Resumen
Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative therapeutic medication should enable the appropriate choice of drinking endpoint. The pharmaceutical industry in collaboration with academia might need to develop new approaches to determining appropriate treatment endpoints with regulatory bodies. The investment risk to industry should be appraised not only in terms of the rather poor results of previous marketing efforts but with a view to the opportunity to penetrate a potentially enormous and largely untapped market.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 271-275 |
| Número de páginas | 5 |
| Publicación | Alcohol and Alcoholism |
| Volumen | 39 |
| N.º | 4 |
| DOI | |
| Estado | Published - jul 2004 |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Toxicology
- Psychiatry and Mental health
Huella
Profundice en los temas de investigación de 'Challenges to medications development in treating alcohol dependence: An international perspective'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver